The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology.
Shenker
A
A
Molecular Pathophysiology Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology* / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D018492:Dopamine Antagonists; D004837:Epinephrine / Q000502:physiology; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D009638:Norepinephrine / Q000502:physiology; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011954:Receptors, Dopamine / Q000187:drug effects*
D000929:Antidepressive Agents, Tricyclic; D000697:Central Nervous System Stimulants; D018492:Dopamine Antagonists; D008996:Monoamine Oxidase Inhibitors; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D009638:Norepinephrine; D004837:Epinephrine